Lates News

According to AI Express of Every Economic News, on May 12th, Great Wall Guorui Securities released a research report giving a buy rating to Hongbo Pharmaceuticals (301230.SZ). The reasons for the rating include: 1) Stable growth in operating income, continuous improvement in profitability; 2) The drug discovery segment maintains steady growth, while the commercialization segment achieves rapid volume growth; 3) The number of active clients in the CRO/CDMO segment is rapidly increasing, and the number of active clients in commercial production and the company's order backlog remain stable; 4) Research and development investment continues to increase, and the development of the large biological medicine model DiOrion-GPT based on generative AI is progressing smoothly.